Stryker Corporation has announced a definitive merger agreement to acquire Entellus Medical Inc. for USD 24.00 per share, or an equity value of approximately USD 662 million. Entellus is a high-growth global medical technology company focused on delivering superior patient and physician experiences through products designed for the minimally invasive treatment of various ear, nose, and throat (ENT) disease states. Founded in 2006, and headquartered in Plymouth, Minnesota, the company has a broad portfolio of ENT products, including the XprESS Multi-Sinus Dilation System and the LATERA Absorbable Nasal Implant, which are highly complementary to the existing ENT portfolio of Stryker’s Instruments business.
The combination of Stryker’s established commitment to making healthcare better and Entellus’ innovative products within the ENT segment will continue to provide customers the tools they need for cost-effective solutions. The closing of this transaction is subject to approval by Entellus’ stockholders, expiration or termination of the applicable waiting period under the Hart–Scott–Rodino Antitrust Improvements Act, and other customary closing conditions. The transaction is expected to be dilutive to Stryker’s 2018 adjusted net earnings per diluted share by approximately USD 0.04 and accretive thereafter.
Guggenheim Securities served as financial advisor and Skadden, Arps, Slate, Meagher & Flom LLP served as outside legal counsels for Stryker in connection with this transaction.